Previous Close | 0.7389 |
Open | 0.7430 |
Bid | 0.7100 x 3000 |
Ask | 0.7350 x 1300 |
Day's Range | 0.6680 - 0.7590 |
52 Week Range | 0.6680 - 8.1000 |
Volume | |
Avg. Volume | 87,248 |
Market Cap | 5.83M |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.9060 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for APDN
STONY BROOK, N.Y., June 29, 2022--Applied DNA expands industry awareness of LinearDNA platform as an alternative to plasmid DNA for therapeutic applications.
STONY BROOK, N.Y., June 21, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in cell-free, enzymatic DNA production, has been increasing its engagement with all stakeholders in anticipation of the June 21, 2022, effective date of the "rebuttable presumption" standard under the Uyghur Forced Labor Prevention Act (UFLPA) signed into law on December 23, 2021. Under the UFLPA, all imports that originate from China's Xinjiang Uyghur Autonomous Region (XUAR) or otherwise use U
STONY BROOK, N.Y. and ROME, Italy, June 06, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. ("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA’s LinearDNA™ platform to produce veterinary DNA cancer vaccines. LinearDNA is Applied DNA's proprietary, lar